| A Study to Evaluate the Safety, Tolerability, and Drug Levels of Danicamtiv in Healthy Japanese and Caucasian Participants (NCT05806359) | Bristol-Myers Squibb | 2023-03-31 |
| A Study to Evaluate the Drug Levels, Safety, and Tolerability of BMS-986278 in Healthy Chinese Participants (NCT05805904) | Bristol-Myers Squibb | 2023-03-29 |
| A Study to Evaluate the Safety, Tolerability and Drug Levels of BMS-986447 in Healthy Participants (NCT05760937) | Bristol-Myers Squibb | 2023-03-10 |
| A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma (NCT05625399) | Bristol-Myers Squibb | 2023-03-06 |
| Mavacamten in Obstructive Hypertrophic Cardiomyopathy (NCT07168655) | Bristol-Myers Squibb | 2023-02-21 |
| A Study to Evaluate the Effects of Mavacamten in Healthy Participants (NCT05719805) | Bristol-Myers Squibb | 2023-02-20 |
| A Study of Mezigdomide in Healthy Participants and Participants With Hepatic Impairment (NCT05707390) | Bristol-Myers Squibb | 2023-02-20 |
| A Study to Evaluate the Safety and Tolerability of Cendakimab in Chinese Healthy Participants (NCT05638282) | Bristol-Myers Squibb | 2023-02-15 |
| A Study of MORAb-202 Versus Investigator's Choice Chemotherapy in Female Participants With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (NCT05613088) | Bristol-Myers Squibb | 2023-02-01 |
| A Study to Evaluate the Effect of Deucravacitinib on Quality of Life in Participants With Plaque Psoriasis in a Community Setting (NCT05701995) | Bristol-Myers Squibb | 2023-01-31 |
| A Study to Evaluate the Efficacy, Safety, and Tolerability of MYK-224 in Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy (NCT05556343) | Bristol-Myers Squibb | 2023-01-18 |
| A Study to Evaluate the Absorption, Metabolism, and Excretion (ADME) of BMS-986435 (NCT05686096) | Bristol-Myers Squibb | 2023-01-16 |
| A Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE) (NCT05617677) | Bristol-Myers Squibb | 2023-01-12 |
| A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (NCT05620407) | Bristol-Myers Squibb | 2023-01-12 |
| A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2) (NCT05552976) | Bristol-Myers Squibb | 2023-01-10 |
| A Study of Absorption, Metabolism, and Elimination CC-90010 in Participants With Advanced Solid Tumors (NCT05678283) | Bristol-Myers Squibb | 2023-01-09 |
| A Study to Assess the Effects on the Single-Dose Drug Levels of Mavacamten in Healthy Participants (NCT05658146) | Bristol-Myers Squibb | 2023-01-06 |
| A Study Investigating the Safety, Tolerability, Drug Levels and Drug Effect of BMS-986278 in Healthy Adult Participants (Part 1) and Japanese Participants (Part 2) (NCT05684289) | Bristol-Myers Squibb | 2023-01-03 |
| An Open-label Study of Ozanimod in Moderate to Severe Ulcerative Colitis in Clinical Practice (NCT05369832) | Bristol-Myers Squibb | 2022-12-16 |
| A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Participants With International Prognostic Scoring System Revised (IPSS-R) Low- or Intermediate-risk Myelodysplastic Syndrome (MDS) (NCT05469737) | Bristol-Myers Squibb | 2022-12-14 |
| A Study of Mavacamten in Non-Obstructive Hypertrophic Cardiomyopathy (NCT05582395) | Bristol-Myers Squibb | 2022-12-14 |
| A Study of BMS-986360/CC-90001 Alone and in Combination With Chemotherapy or Nivolumab in Advanced Solid Tumors (NCT05625412) | Bristol-Myers Squibb | 2022-12-09 |
| A Study to Evaluate Efficacy and Long-term Safety of Oral Ozanimod in Chinese Participants With Moderately to Severely Active Ulcerative Colitis (UC) (NCT05644665) | Bristol-Myers Squibb | 2022-12-09 |
| A Study to Determine the Efficacy and Safety of Luspatercept in Adult Participants and to Evaluate the Safety and Pharmacokinetics in and Adolescent Participants With Alpha (α)-Thalassemia (NCT05664737) | Bristol-Myers Squibb | 2022-12-09 |
| A Study to Assess Deucravacitinib Post-marketing Surveillance in Participants With Psoriasis in Japan (NCT05633264) | Bristol-Myers Squibb | 2022-12-05 |
| A Study to Evaluate Nivolumab in Japanese Participants With Muscle-invasive Urothelial Carcinoma (NCT05779592) | Bristol-Myers Squibb | 2022-11-23 |
| A Study of MORAb-202 in Participants With Previously Treated Metastatic Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma (AC) (NCT05577715) | Bristol-Myers Squibb | 2022-11-14 |
| A Study Investigating Interactions Between BMS-986322 and Rosuvastatin, Metformin and Methotrexate in Healthy Participants (NCT05615012) | Bristol-Myers Squibb | 2022-11-11 |
| A Study to Assess Treatment Patterns, Clinical Outcomes and Healthcare Resource Utilization Among Adult Participants With Moderate-To-Severe Plaque Psoriasis (NCT05547490) | Bristol-Myers Squibb | 2022-10-31 |
| A Study to Investigate the Interaction of BMS-986322 and a Combined Oral Hormonal Contraceptive (Ethinyl Estradiol [EE]/Norethindrone [NET]) in Healthy Female Participants (NCT05579574) | Bristol-Myers Squibb | 2022-10-21 |
| A Study to Evaluate the Metabolism and Excretion of BMS-986369 in Healthy Male Participants (NCT05567510) | Bristol-Myers Squibb | 2022-10-20 |
| A Study of Nivolumab, Ipilimumab, and Chemotherapy in Participants With Non-small Cell Lung Cancer (NCT05599685) | Bristol-Myers Squibb | 2022-10-19 |
| A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma (NCT05372354) | Bristol-Myers Squibb | 2022-10-18 |
| A Study to Evaluate Luspatercept (ACE-536) in Chinese Participants Who Require Regular Red Blood Cell Transfusions Due to Beta (β)-Thalassemia. (NCT05567458) | Bristol-Myers Squibb | 2022-10-17 |
| Efficacy and Safety of Deucravacitinib Versus Placebo in Participants With Moderate-to-severe Scalp Psoriasis (NCT05478499) | Bristol-Myers Squibb | 2022-10-06 |
| A Study of BMS-986442 With Nivolumab With or Without Chemotherapy in Solid Tumors and Non-small Cell Lung Cancer (NCT05543629) | Bristol-Myers Squibb | 2022-10-04 |
| A Study to Assess BMS-986207 in Combination With Nivolumab and Ipilimumab as First-line Treatment for Participants With Stage IV Non-Small Cell Lung Cancer (NCT05005273) | Bristol-Myers Squibb | 2022-10-03 |
| A Real-world Observational Study to Compare Effectiveness of Deucravacitinib Vs Apremilast in Adults With Plaque Psoriasis (NCT05744466) | Bristol-Myers Squibb | 2022-09-30 |
| A Taste Assessment of Iberdomide and Mezigdomide in Healthy Participants (NCT05539976) | Bristol-Myers Squibb | 2022-09-30 |
| A Study to Assess the Safety and Tolerability of BMS-986322 in Healthy Participants of Japanese Descent (NCT05546151) | Bristol-Myers Squibb | 2022-09-28 |
| A Study to Evaluate the Safety and Tolerability of BMS-986403 in Participants With Relapsed and/or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (NCT05244070) | Bristol-Myers Squibb | 2022-09-14 |
| A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma (NCT05255601) | Bristol-Myers Squibb | 2022-09-13 |
| A Phase 1, First-in-Human Study of BMS-986421 in Healthy Participants (NCT05517837) | Bristol-Myers Squibb | 2022-09-13 |
| An Efficacy and Safety Study of Oral Azacitidine (CC-486) as Maintenance Therapy in Chinese Participants With Acute Myeloid Leukemia in Complete Remission (NCT05413018) | Bristol-Myers Squibb | 2022-08-19 |
| A Study of Mavacamten in Obstructive Hypertrophic Cardiomyopathy (NCT05414175) | Bristol-Myers Squibb | 2022-08-19 |
| A Study to Evaluate the Safety and Tolerability of BMS-986408 Alone and in Combination With Nivolumab or Nivolumab and Ipilimumab in Participants With Advanced Solid Tumors (NCT05407675) | Bristol-Myers Squibb | 2022-08-02 |
| A Study to Compare Nivolumab Administered Subcutaneously vs Intravenous in Melanoma Participants Following Complete Resection (NCT05297565) | Bristol-Myers Squibb | 2022-08-02 |
| Real-World Outcomes in Relapsed/Refractory Multiple Myeloma Patients Treated, or Eligible for Treatment, With Idecabtagene Vicleucel (NCT06154902) | Bristol-Myers Squibb | 2022-07-29 |
| Study of Relatlimab in Combination With Nivolumab in Chinese Participants (NCT05498480) | Bristol-Myers Squibb | 2022-07-27 |
| A Study on the Safety of Ozanimod Exposure in Pregnant Women and Their Offspring (NCT05170126) | Bristol-Myers Squibb | 2022-07-15 |
| A Study of the Effectiveness and Safety of Nivolumab Plus Chemotherapy in Participants With Untreated Advanced/Recurrent Gastric Cancer (NCT05334719) | Bristol-Myers Squibb | 2022-06-29 |
| A Study to Evaluate the Drug Levels of BMS-986166 in Healthy Male Participants (NCT05409157) | Bristol-Myers Squibb | 2022-06-17 |
| A Study to Assess the Drug Levels of CC-92480 After Coadministration With Rifampin and Itraconazole, and the Drug Levels of Digoxin and Rosuvastatin After Coadministration With CC-92480 in Healthy Participants (NCT05389722) | Bristol-Myers Squibb | 2022-06-09 |
| Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion (NCT05245500) | Bristol-Myers Squibb | 2022-06-09 |
| A Study to Evaluate the Utilization, Effectiveness, and Quality of Life of Ozanimod in Participants With Ulcerative Colitis (NCT05382715) | Bristol-Myers Squibb | 2022-05-30 |
| A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative Colitis (NCT05076175) | Bristol-Myers Squibb | 2022-05-30 |
| A Study to Evaluate the Effects on the Single-Dose Drug Levels of Mavacamten in Healthy Participants (NCT05362045) | Bristol-Myers Squibb | 2022-05-16 |
| A Study to Compare the Drug Levels of Atazanavir and Cobicistat Between the Coadministration of Age-Appropriate Mini-Tablet Formulations and the Coadministration of the Individual Reference Products in Healthy Adults Under Fed Conditions (NCT05236738) | Bristol-Myers Squibb | 2022-05-13 |
| A Study to Evaluate the Drug Levels of [14C]CC-99677 in Healthy Male Participants (NCT05284890) | Bristol-Myers Squibb | 2022-05-12 |
| A Study of Nivolumab and Relatlimab in Combination With Bevacizumab in Advanced Liver Cancer (NCT05337137) | Bristol-Myers Squibb | 2022-05-05 |
| A Study of Nivolumab-relatlimab Fixed-dose Combination Versus Regorafenib or TAS-102 in Participants With Later-lines of Metastatic Colorectal Cancer (NCT05328908) | Bristol-Myers Squibb | 2022-04-28 |
| A Study to Evaluate the Effect of Activated Charcoal With Sorbitol on the Single-dose of Mavacamten in Healthy Participants (NCT05320094) | Bristol-Myers Squibb | 2022-04-15 |
| A Study to Assess Relative Bioavailability of Branebrutinib, From a Tablet Formulation to the Capsule Formulation, the Effect of Food on the Bioavailability of Branebrutinib From a Tablet Formulation, and the Safety and Drug Levels of Branebrutinib From a Tablet Formulation in Healthy Participants (NCT05303220) | Bristol-Myers Squibb | 2022-04-08 |
| A Study of BMS-986406 as Monotherapy and Combination Therapies in Participants With Advanced Tumors (NCT05298592) | Bristol-Myers Squibb | 2022-03-31 |
| A Study to Evaluate BMS-986141 Added on to Aspirin or Ticagrelor or the Combination, on Thrombus Formation in a Thrombosis Chamber Model in Participants With Stable Coronary Artery Disease and Healthy Participants (NCT05093790) | Bristol-Myers Squibb | 2022-03-25 |
| A Study of Azacitidine in Participants With International Prognostic Scoring System (IPSS) Intermediate-2 and High-risk Myelodysplastic Syndromes (MDS), or Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) (NCT05218902) | Bristol-Myers Squibb | 2022-02-25 |
| A Study Assessing the Health-Related Quality of Life (HRQoL) in Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM) With Triple Class Exposure (NCT05217082) | Bristol-Myers Squibb | 2022-02-22 |
| A Study of Nivolumab Plus Chemotherapy in First Line Treatment of Adult Participants With Advanced or Metastatic Gastric Cancer (NCT05165264) | Bristol-Myers Squibb | 2022-02-16 |
| A Study of BMS-986218 or BMS-986218 Plus Nivolumab in Combination With Docetaxel in Participants With Metastatic Castration-resistant Prostate Cancer (NCT05169684) | Bristol-Myers Squibb | 2022-02-14 |
| A Study to Evaluate Nivolumab in Combination With Ipilimumab Versus Pemetrexed With Cisplatin or Carboplatin for Unresectable Pleural Mesothelioma in Chinese Participants (NCT05136677) | Bristol-Myers Squibb | 2022-01-25 |
| A Study to Assess the Effect of CC-95251 in Participants With Acute Myeloid Leukemia and Myelodysplastic Syndromes (NCT05168202) | Bristol-Myers Squibb | 2022-01-19 |
| A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Best Supportive Care as Maintenance Therapy in Japanese Participants With Acute Myeloid Leukemia (AML) in Complete Remission (NCT05197426) | Bristol-Myers Squibb | 2022-01-17 |
| A Study of Yervoy and Opdivo Combination Therapy in Participants With Unresectable Advanced/Recurrent Malignant Pleural Mesothelioma (MPM) (NCT05324436) | Bristol-Myers Squibb | 2022-01-08 |
| A Study to Evaluate the Effect of Co-administration of Itraconazole or Diltiazem on the Single-dose of Danicamtiv in Healthy Participants (NCT05162222) | Bristol-Myers Squibb | 2021-12-15 |
| A Study to Evaluate the Safety, Tolerability, Kinetics, Biodistribution and Repeatability of 11C-BMS-986196 After Intravenous (IV) Administration in Healthy Participants and After Repeat IV Administration in Participants With Multiple Sclerosis (NCT05064436) | Bristol-Myers Squibb | 2021-12-10 |
| A Study to Assess Safety of Relatlimab With Ipilimumab in Participants With Advanced Melanoma Who Progressed on Anti-Programmed Cell Death Protein 1 (Anti-PD-1) Treatment (NCT03978611) | Bristol-Myers Squibb | 2021-12-09 |
| A Study of Preferences for the First-Line Treatment of Advanced/Metastatic Non-Small Cell Lung Cancer (NCT05250817) | Bristol-Myers Squibb | 2021-12-09 |
| A Study to Assess Relatlimab and Nivolumab Fixed-dose Combination in Chinese Participants With Advanced Solid Tumors (NCT05134948) | Bristol-Myers Squibb | 2021-11-30 |
| A Study to Assess Adjuvant Immunotherapy With Nivolumab Plus Relatlimab Versus Nivolumab Alone After Complete Resection of Stage III-IV Melanoma (NCT05002569) | Bristol-Myers Squibb | 2021-10-19 |
| Measuring the Treatment Preferences of Participants in Japan With Moderate-to-Severe Psoriasis (PsO) Using Discrete Choice Experiment (NCT05065762) | Bristol-Myers Squibb | 2021-10-01 |
| A Study to Evaluate the Bioavailability of Fedratinib When Administered in Different Ways to Healthy Adult Participants (NCT05051553) | Bristol-Myers Squibb | 2021-09-21 |
| A Study to Compare the Response to Treatment With Abatacept vs Adalimumab, on Background Methotrexate, in Adults With Early, Seropositive, and Shared Epitope-positive Rheumatoid Arthritis and an Inadequate Response to Methotrexate (NCT04909801) | Bristol-Myers Squibb | 2021-09-15 |
| Taste Assessment of Ozanimod (NCT05001152) | Bristol-Myers Squibb | 2021-09-09 |
| A Post-Authorization, Long-term Study of Ozanimod Real-world Safety (NCT05605782) | Bristol-Myers Squibb | 2021-09-02 |
| A Study of BMS-986166 or Branebrutinib for the Treatment of Participants With Atopic Dermatitis (NCT05014438) | Bristol-Myers Squibb | 2021-08-17 |
| A Study of BMS-986416 With and Without Nivolumab in Select Solid Tumors (NCT04943900) | Bristol-Myers Squibb | 2021-08-09 |
| A Study to Characterize the Drug Levels of an Oral Contraceptive With and Without BMS-986166 in Healthy Female Participants of Childbearing Potential (NCT04934696) | Bristol-Myers Squibb | 2021-08-03 |
| A Study to Assess Real-World Patient-Reported Outcomes With Fedratinib for Myelofibrosis Post-Ruxolitinib (NCT05665192) | Bristol-Myers Squibb | 2021-08-02 |
| A Study to Assess the Effect of Itraconazole, Phenytoin and Gemfibrozil on the Drug Levels of BMS-986166 in Healthy Participants (NCT04956627) | Bristol-Myers Squibb | 2021-07-28 |
| A Study to Evaluate the Benefits and Risks of Conversion of Existing Adolescent Kidney Transplant Recipients Aged 12 to <18 Years to a Belatacept-based Immunosuppressive Regimen as Compared to Continuation of a Calcineurin Inhibitor-based Regimen, and Their Adherence to Immunosuppressive Medications (NCT04877288) | Bristol-Myers Squibb | 2021-07-21 |
| A Study to Evaluate the Drug Levels of Deucravacitinib From Tablets After Oral Administration in Healthy Participants (NCT04949269) | Bristol-Myers Squibb | 2021-07-20 |
| A Study of Milvexian Using an IV Microtracer With Additional Formulation and Food Effect Comparison in Healthy Participants (NCT04965389) | Bristol-Myers Squibb | 2021-07-16 |
| A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of BMS-986166 in Healthy Japanese Participants (NCT04965402) | Bristol-Myers Squibb | 2021-07-15 |
| A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNFα Inhibitor Treatment (NCT04908189) | Bristol-Myers Squibb | 2021-07-15 |
| A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease-modifying Anti-rheumatic Drugs (NCT04908202) | Bristol-Myers Squibb | 2021-07-13 |
| A Study to Evaluate Efficacy and Safety of Deucravacitinib in Participants With Active Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) (NCT04857034) | Bristol-Myers Squibb | 2021-07-12 |
| A Study of Treatment Patterns and Clinical Outcomes of Psoriasis in Japan (NCT04826536) | Bristol-Myers Squibb | 2021-06-25 |
| A Study to Determine the Effect of Famotidine on the Drug Levels of BMS-986256 in Healthy Participants (NCT04941755) | Bristol-Myers Squibb | 2021-06-25 |
| A Study to Evaluate the Drug Levels and Safety of Pegbelfermin in Healthy Overweight and Obese Chinese and Korean Participants (NCT04649710) | Bristol-Myers Squibb | 2021-06-21 |
| A Study to Assess the Safety, Tolerability and Drug Levels of BMS-986172 in Healthy and Obese Participants, Including an Assessment of the Effects of Food on BMS-986172 Absorption (NCT04926051) | Bristol-Myers Squibb | 2021-06-15 |